return to corporate website
Return to www.noxopharm.com

Noxopharm (ASX:NOX)

Delivering Science. Transforming Lives

Learn more
Discover More

INVESTOR PRESENTATIONS

Noxopharm CEO Discusses Veyonda® Orphan Drug Designation by US FDA
24 March 2022
See More >

SHARE PRICE

Mkt Cap:
(20 minutes delay)
View Share Price >
Noxopharm is pioneering life-changing therapies through innovative science.
NOXOPHARM & VEYONDA
Noxopharm's drug development pipelines is focused on developing new treatment options for a broad range of solid tumour cancers and septic shock. Both areas of unmet medical needs.
Noxopharm's current lead drug candidate is Veyonda®, currently being tested in several cancer trials, and also in at-risk COVID-19 patients, for its ability to harness the power of the immune system.
LATEST ASX ANNOUNCEMENTS
Why Invest in Noxopharm >
Corporate Videos >
Latest Media >
FOUR R&D BUSINESSES IN ONE COMPANY
Veyonda®
Cancer treatment
enhancement >
Cancer Research
Pipeline
Cancer growth
factor inhibitors >
Veyonda®
Septic shock >
Chronic inflammatory
diseases/autoimmune
diseases >
 

Noxopharm History

Noxopharm, an Australian drug discovery and development company, was founded in 2015 by Dr Graham Kelly, whose lifetime of scientific research in the unique isoflavonoid biotechnology platform led him to establishing his third public company.
View History

Quick Links

Location

Address
Noxopharm Limited
Level 20, Tower A, The Zenith
821 Pacific Highway
CHATSWOOD NSW 2067
or
PO Box 292, Gordon 2072. NSW AUSTRALIA

Telephone:
+ 61 2 9144 2223

ABN
50 608 966 123

Contact us

Email
Shareholder enquiries:
info@noxopharm.com
Patient enquiries:
medical.information@noxopharm.com
Phone: +61 2 9144 2223

Stay in Touch

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Noxopharm
Site Map Privacy Search
Site by